Recent developments in 99mTc and 123I-radiopharmaceuticals for SPECT imaging

P. V. Kulkarni

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Availability of 123I of high radionuclidic purity has encouraged the development of 123I-based radiopharmaceuticals for the assessment of myocardial fatty acid metabolism, myocardial neuronal activity, and for receptor and antibody imaging. Advances in the chemistry of technetium have resulted in the development of novel agents for myocardial and cerebral perfusion and renal function studies. Monoclonal antibodies labeled with 99mTc show promise for imaging neoplastic lesions, myocardial infarcts, and thrombus localization. Recent developments in 123I and 99mTc agents for myocardial and brain imaging studies are discussed.

Original languageEnglish (US)
Pages (from-to)647-654
Number of pages8
JournalInternational Journal of Radiation Applications and Instrumentation.
Volume18
Issue number6
DOIs
StatePublished - 1991

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Recent developments in <sup>99m</sup>Tc and <sup>123</sup>I-radiopharmaceuticals for SPECT imaging'. Together they form a unique fingerprint.

Cite this